However, ACC at the current doses failed to suppress the expressions of JAK1 (Figure 5(h)) and JAK3 (Figure 5(j)), and displayed a negative regulatory effect on JAK1-JAK3. Here, JAK3 is linked to adrenal cortex carcinoma.